Methods of Hybridoma Formation

  • Arie H. Bartal
  • Yashar Hirshaut

Part of the Contemporary Biomedicine book series (CB, volume 7)

Table of contents

  1. Front Matter
    Pages i-xxv
  2. Arie H. Bartal, Yashar Hirshaut
    Pages 1-40
  3. Arie H. Bartal, Yashar Hirshaut
    Pages 41-61
  4. Robert J. Klebe, Kevin L. Bentley
    Pages 77-96
  5. U. Zimmermann
    Pages 97-149
  6. Arie H. Bartal, Yashar Hirshaut
    Pages 151-161
  7. Arie H. Bartal, Carl Feit, Yashar Hirshaut
    Pages 163-179
  8. Regine J. J. M. Westerwoudt
    Pages 209-230
  9. Danuta Kozbor, Carlo M. Croce
    Pages 273-298
  10. Lennart Olsson
    Pages 299-316
  11. John A. Sogn
    Pages 317-335
  12. Gad Spira, Hector L. Aguila, Ellyn Fischberg, Matthew D. Scharff
    Pages 379-397
  13. Veronica van Heyningen, Simon van Heyningen
    Pages 399-411
  14. Rosalie Ber, Pamela L. Witte
    Pages 413-417
  15. L. de Leij, E. Schwander, T. H. The
    Pages 419-427
  16. David E. Wells
    Pages 429-436
  17. Michael Andreeff, Edith Espiritu
    Pages 437-445
  18. William Cieplinski
    Pages 457-476
  19. Back Matter
    Pages 477-480

About this book


Laymen often consider modern laboratory research to be based on an endless array of sophisticated technologies whose complex capabilities are as important to the outcome of any project as the inventiveness and creativity of the scientists who employ them. Scientists at times may share this point of view until they are con­ fronted by unexpected findings that demand new approaches, and they discover that yesterday's "sophisticated tools" are today's "blunt instruments." This experience provides a more sobering view of the current state of our scientific methods. It also serves as an impetus for the further development of technology that prepares us for the next stage of advance. Immunologists were confronted by such a technological crises in the late 1970s when they finally were forced to admit that poly­ clonal antibodies, although quite sensitive reagents, were not spe­ cific enough to answer many of the questions then confronting virologists and tumor biologists. The answer to the need for specific­ ity came with the development of monoclonal antibody technology. In the last ten years there have been considerable advances in monoclonal antibody techniques. Today these reagents are much more versatile than they were initially and can be applied to a broad range of problems. Still, most workers who are using these anti­ bodies are convinced that their potential is far from exhausted, and that at least in some fields we are currently in the early stages of learning how to use them properly.


DNA Expression Interferon Macrophages Polysaccharide Promoter Termination Transport Viruses Vivo biosynthesis cell lines cloning genes splenocytes

Editors and affiliations

  • Arie H. Bartal
    • 1
    • 2
  • Yashar Hirshaut
    • 3
  1. 1.Biotherapeutics, Inc.FranklinUSA
  2. 2.Hybridoma Laboratory, Northern Israel Oncology CenterRambam Medical CenterHaifaIsrael
  3. 3.Sloan-Kettering Cancer CenterNew YorkUSA

Bibliographic information